oncosil
MEDICAL
ASX.OSL

# CEO AGM Presentation

*Advancing Pancreatic cancer treatment*
*Transforming the prognosis*

**20 October 2020**

# *Commercialising a breakthrough implantable radiotherapy treatment for pancreatic cancer*

# Key Highlights

| | |
|---|---|
| **Europe**<br>LAPC | Continue to progress critical launch preparation activities – we remain on track for first sales in 2020 |
| **ASEAN / APAC**<br>LAPC | Targeting first sales in the region in 2020 - approved in New Zealand, Singapore and Malaysia; awaiting outcomes of registrations filed in Australia and Hong Kong |
| **US**<br>Bile duct cancer | Humanitarian Device Exemption (HDE) application filed with the FDA in July 2020 for the treatment of bile duct cancer; building on OncoSil's dual pronged US market strategy |
| **PanCO update** | Compelling results highlighting OncoSil's downstaging significance, with 60% of patients that underwent surgery alive today with a survival range of 26-35 months post-treatment |
| **Cash position** | Cash balance of approximately A$20.5 million as at 30 September 2020, following the receipt of a R&D Tax Incentive Refund of A$2.8 million |

# Update on key 2020 objectives

## List of milestones achieved since CE Mark in April 2020

| | |
|---|---|
| **Completed ~$19m placement and entitlement offer to fund commercialisation globally** | ✓ |
| **Appointment of Nigel Lange (ex Sirtex Europe CEO) to drive European commercialisation** | ✓ |
| **Humanitarian Device Exemption (HDE) filing with FDA for Bile Duct Cancer** | ✓ |
| **Regulatory filing in Australia** | ✓ |
| **Regulatory clearance in Singapore** | ✓ |
| **Regulatory clearance in Malaysia** | ✓ |

**Status** ✓ Yes ✓ In part ✗ No

## Upcoming catalysts

- **Expected first sale in UK/EU** – 2H CY20
- **Regulatory decision in US for Bile Duct Cancer** – anticipated Q4 CY20 (or Q1 CY 21)[1]
- **Regulatory clearance in Australia** – anticipated 1H CY21[2]
- **Regulatory decision in Hong Kong** – anticipated 2H CY20[2]

**Notes.**

[1] 75 day review subject to FDA process and questions which may delay decision

[2] Subject to Regulatory process and questions which may delay decision timing

# Treating pancreatic cancer is challenging and difficult

## Existing treatments for pancreatic cancer are ineffective...




### Late diagnosis

- Symptoms often unnoticed until cancer has metastasised

### Sub-optimal current standard of care

- Surgery - not feasible in 85% of patients
- Chemotherapy - limited effectiveness and very toxic
- Radiation therapy - toxic to the patient's GI tract

### Limited advancements in past 20 years

- Only two drugs to have made significant improvements in pancreatic cancer; last approved in 2013
- Median overall survival has only increased by 2 months (to 8.5 months)

## ...resulting in very poor survival rates[1]

**~8.5 months**

Overall median survival

**<5% chance**

Reaching 5-year survival mark

**Notes.**

(1) Loehrer PJ et al. J Clin Oncol 2011Nov 1;29 (31) 4105-12

# The OncoSil™ device provides a unique and effective solution

## Radiation therapy delivered directly into the tumour

### OncoSil™ has clinically proven to prolong median overall survival in LAPC patients







Reduction in the risk of death compared to CT-only and ICT + CCRT studies [2]




One-year survival rate in the per protocol population




Increase to 9.3 months in median PFS compared to CT-only and ICT + CCRT studies [2]

***Survival length of ~16 months is based on data taken in May 2019, the time of the latest analysis***

**Notes.**

(1) Loehrer PJ et al. J Clin Oncol 2011Nov 1;29 (31) 4105-12

(2) LAPC = Locally advanced pancreatic cancer; CT = Systemic Chemotherapy; ICT = Induction Chemotherapy; CCRT = Consolidated Chemotherapy

# Updated analysis on resected cohort illustrates potential to convert inoperable patients to operable status

## 42 patients treated

- 42 patients with unresectable, locally advanced pancreatic cancer (uLAPC) enrolled in the PanCO trial
- All patients were initially determined to be inoperable or medically unfit for surgery
- Typically, survival lengths of uLAPC patients is ~8.5 months[1]

**All were implanted with the OncoSil™ device**

## 10 underwent surgery

- 14 were sufficiently downstaged to be technically considered for surgical resection
- 4 of these patients were unable to undergo surgery due to co-morbidities or other considerations
- 10 patients subsequently underwent surgery, thus forming the resected cohort sub-group

**This leads to a technical resection rate of 33%**

## 6 remain alive with >26 months survival post-treatment

- OncoSil completed an updated analysis in July 2020 on the resected cohort sub-group:
  - Median follow-up of 31.1 months
  - 4 deaths have been reported to date (at 18.8, 20.9, 21.0 and 22.1 months)
  - 60% of patients remain alive today with a survival range of 26-35 months post-treatment

**Analysis highlights potential to "convert" previously deemed inoperable patients to operable status**

**Notes.**

(1) Loehrer PJ et al. J Clin Oncol 2011Nov 1;29 (31) 4105-12

# Clear market opportunity for OncoSil to become standard of care in LAPC

## There are more than 40k locally advanced pancreatic cancer (LAPC) cases p.a. in EU & UK [1,2]

| | Disease prognosis | | Current treatment | OncoSil solution |
|---|---|---|---|---|
| *Future focus* |   | **Resectable** | Surgery | OncoSil™ could be used to downstage tumours prior to surgery to improve surgical outcomes |
| *Current focus* |   | **Locally Advanced** | Chemotherapy<br>Radiation therapy | OncoSil™ provides treatment to shrink tumours, reduce pain, downstage to surgery and prolong survival |
| *Future focus* |   | **Metastatic** | Chemotherapy | Unlikely to benefit overall survival but OncoSil™ may be used to control tumour growth, alleviate pain and improve quality of life |

oncosil MEDICAL

**Promising opportunity to become the standard of care**

- ✓ A form of radiation therapy, to be used in combination with chemotherapy
- ✓ More concentrated radiation compared to external beam radiation
- ✓ Safer use than external beam radiation as it does not impact healthy tissue

**Notes.**
(1) GLOBOCAN 2018: Estimated Cancer Incidence Worldwide in 2018 (IARC/WHO)
(2) Based on LAPC cases equating to 40% of all pancreatic cancer cases

# European commercialisation update

| | |
|---|---|
| **Sales force and recruitment** | ✓ 9 direct OncoSil sales force and training resource in place in UK, Germany, Italy, Benelux<br>✓ Sales force recruitment continues |
| **Hospital onboarding** | ✓ Central Radio-pharmacy (CRP) established & contracted to service up 15 hospital in the Greater London area<br>✓ Multiple hospitals onboard with site training and certification continuing |
| **Patient registry** | ✓ OSPREY Patient Registry “operationally ready” to support commercialisation |
| **Training** | ✓ Authorised Users - Nuclear Medicine Physicians, Interventional Radiologist & Radiation Oncologists: 10<br>✓ Authorised Users - Endoscopist: 2 (7 more to be training covering multiple sites)<br>✓ Authorised Dispensers – Radiation Physicists and Nuclear Medicine Technicians: 25<br>✓ Endoscopy Nurses – 5<br>✓ Cold Dose Dilutions (CRP): 7 |

# Important notice

This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (**OncoSil** or the **Company**) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the information contained should be read in conjunction with past and future ASX announcements made by OncoSil and should not be relied upon as an independent source of information. Please contact OncoSil and/or refer to the Company's website www.oncosil.com.au for further information.

**Not an Offer for Securities**

Nothing in this Presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in the Company, in any jurisdiction. This presentation is not exhaustive of all of the information a potential investor or their professional advisers would require. This presentation does NOT constitute a “Prospectus" or a "Disclosure Document” (as defined in the Corporations Act 2001 (Cth) (Corporations Act)) and has not been, and will not be, lodged with the Australian Securities and Investments Commission or any other regulatory authority. Accordingly it is not required to contain, and may not necessarily contain, all of the information that a Prospectus or like Disclosure Document would be required to contain pursuant to the Corporations Act.

**Forward-Looking Statements**

This document contains certain forward-looking statements as at the date of this presentation relating to OncoSil’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other national and international authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales, nor that that any specific objective of the Company will be achieved or that any particular performance of the Company or of its shares will be achieved. In particular, the Company's expectations regarding the approval and commercialisation of the product candidates could be affected by, amongst other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; changes in legislation or regulatory requirements, our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our Company, products, product candidates, financial results and business prospects. Should one or more of these changes, risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. There is NO guarantee of future performance - actual results and future outcomes will in all likelihood differ from those outlined herein. You are urged to consider all of the above and advice from your own advisers carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The information in this presentation is not financial product advice, is not an offer to invest in the securities of OncoSil and does not take into account your investment position or objectives, financial situation or any particular requirements. For these and other reasons, you are strongly recommended to obtain your own up to date independent legal, financial and investment advice – those acting without such advice do so at their own risk.

**Disclaimer**

This Presentation and any supplemental materials have been prepared by OncoSil based on available information. Although reasonable care has been taken to ensure the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness, or correctness of such information and opinions and no reliance should be placed on such information or opinions. To the maximum extent permitted by law, none of OncoSil or any of its members, directors, officers, employees, or agents or corporate advisors, nor any other person accepts any liability whatsoever for any loss, however arising, from the use of the presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability arising from fault or negligence on the part of OncoSil or any of its directors, officers, employees or agents.

The information contained in this presentation is current as at 20 October 2020.

**Daniel Kenny**
CEO & Managing Director
**E:** daniel.kenny@oncosil.com

OncoSil Medical Ltd
www.oncosil.com

**T:** +61 2 9223 3344
**F:** +61 2 9252 3988

oncosil
MEDICAL